{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T15:12:04Z","timestamp":1788189124534,"version":"build-2803163510"},"reference-count":92,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic Chemistry"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.bioorg.2025.109140","type":"journal-article","created":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T06:43:25Z","timestamp":1761201805000},"page":"109140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The emerging role of Oxadiazole derivatives as VEGFR and EGFR inhibitors in Cancer therapy"],"prefix":"10.1016","volume":"166","author":[{"given":"Rajarshi","family":"Nath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biplab","family":"Debnath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anhic","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shah Alam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arindam","family":"Maity","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Jawaid","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bioorg.2025.109140_bb0005","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","article-title":"The role of VEGF and EGFR inhibition: implications for combining anti\u2013VEGF and anti\u2013EGFR agents","volume":"5","author":"Tabernero","year":"2007","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0010","doi-asserted-by":"crossref","first-page":"5298","DOI":"10.3390\/ijerph19095298","article-title":"Expression of VEGF, EGF, and their receptors in squamous esophageal mucosa, with correlations to histological findings and endoscopic minimal changes, in patients with different GERD phenotypes","volume":"19","author":"Wasielica-Berger","year":"2022","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"10.1016\/j.bioorg.2025.109140_bb0015","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.3390\/cancers16061188","article-title":"Investigating the efficacy of EGFR-TKIs and anti-VEGFR combination in advanced non-small cell lung cancer: a meta-analysis","volume":"16","author":"Sakharkar","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.109140_bb0020","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.3390\/molecules26041076","article-title":"Molecular targeting of epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR)","volume":"26","author":"Kaufman","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109140_bb0025","doi-asserted-by":"crossref","first-page":"3159","DOI":"10.1021\/acs.biochem.7b00399","article-title":"Parallels and distinctions in FGFR, VEGFR, and EGFR mechanisms of transmembrane signaling","volume":"56","author":"Sarabipour","year":"2017","journal-title":"Biochemistry"},{"key":"10.1016\/j.bioorg.2025.109140_bb0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jtho.2020.10.006","article-title":"Dual EGFR-VEGF pathway inhibition: a promising strategy for patients with EGFR-mutant NSCLC","volume":"16","author":"Le","year":"2021","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.bioorg.2025.109140_bb0035","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.bjc.6603791","article-title":"Dual inhibition of EGFR and VEGFR pathways in combination with irradiation: antitumour supra-additive effects on human head and neck cancer xenografts","volume":"97","author":"Bozec","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bioorg.2025.109140_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdl962","article-title":"Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy","volume":"17","author":"Ciardiello","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.109140_bb0045","first-page":"141","article-title":"A review: biological importance of heterocyclic compounds","volume":"9","author":"Al-Mulla","year":"2017","journal-title":"Der Pharma Chem"},{"key":"10.1016\/j.bioorg.2025.109140_bb0050","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.ejmech.2016.12.014","article-title":"Design, synthesis, docking and QSAR study of substituted benzimidazole linked oxadiazole as cytotoxic agents, EGFR and erbB2 receptor inhibitors","volume":"126","author":"Akhtar","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0055","doi-asserted-by":"crossref","first-page":"130315","DOI":"10.1016\/j.bmcl.2025.130315","article-title":"Design, synthesis, and evaluation of 1, 3, 4-oxadiazole-based EGFR inhibitors","volume":"127","author":"Tang","year":"2025","journal-title":"Biorg, Med. Chem. Lett."},{"key":"10.1016\/j.bioorg.2025.109140_bb0060","article-title":"Unveiling the therapeutic potential of 1, 2, 4-oxadiazole derivatives: an updated review","volume":"102271","author":"Khasawneh","year":"2025","journal-title":"Results in Chemistry"},{"key":"10.1016\/j.bioorg.2025.109140_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e38294","article-title":"Synthesis of designed new 1, 3, 4-oxadiazole functionalized pyrano [2, 3-f] chromene derivatives and their antimicrobial activities","volume":"10","author":"Alatawi","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.bioorg.2025.109140_bb0070","first-page":"2","article-title":"Facile synthesis of some novel derivatives of 1, 3, 4-oxadiazole derivatives associated with quinolone moiety as cytotoxic and antibacterial agents","volume":"6","author":"Sudeesh","year":"2017","journal-title":"Org Chem Curr Res"},{"key":"10.1016\/j.bioorg.2025.109140_bb0075","first-page":"594","article-title":"Synthesis and characterization of some novel oxadiazoles for in\u2013vitro anti-inflammatory activity","volume":"2","author":"Nimavat","year":"2012","journal-title":"Int J Res Pharm Chem"},{"key":"10.1016\/j.bioorg.2025.109140_bb0080","first-page":"285","article-title":"Review on synthesis and spectral analysis of 1, 3, 4-oxa\/thiadiazole moiety based on their literature support, world journal of","volume":"8","author":"Garewal","year":"2019","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0085","doi-asserted-by":"crossref","first-page":"5474","DOI":"10.1038\/s41598-024-55046-0","article-title":"New oxadiazole and pyrazoline derivatives as anti-proliferative agents targeting EGFR-TK: design, synthesis, biological evaluation and molecular docking study","volume":"14","author":"Serag","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bioorg.2025.109140_bb0090","doi-asserted-by":"crossref","first-page":"100265","DOI":"10.1016\/j.ejmcr.2025.100265","article-title":"T.K. Maity, 1, 3, 4-Oxadiazole based EGFR inhibitors as anticancer therapeutics: SAR study and binding mode of interaction analysis","volume":"14","author":"Samanta","year":"2025","journal-title":"European Journal of Medicinal Chemistry Reports"},{"key":"10.1016\/j.bioorg.2025.109140_bb0095","doi-asserted-by":"crossref","first-page":"32778","DOI":"10.1039\/D5RA03702F","article-title":"A two-decade overview of oxadiazole derivatives as promising anticancer agents","volume":"15","author":"Salem","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109140_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmcr.2022.100058","article-title":"Oxadiazole derivatives: histone deacetylase inhibitors in anticancer therapy and drug discovery","volume":"5","author":"Matore","year":"2022","journal-title":"European Journal of Medicinal Chemistry Reports"},{"key":"10.1016\/j.bioorg.2025.109140_bb0105","article-title":"Benzimidazole-based hybrids as inhibitors of EGFR\/VEGFR-2 and their combinations with other enzymes: design, synthesis, and activity","volume":"108920","author":"Mavrova","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0110","doi-asserted-by":"crossref","first-page":"6187","DOI":"10.1111\/febs.16133","article-title":"Calcium signaling in cancer progression and therapy","volume":"288","author":"Wu","year":"2021","journal-title":"FEBS J."},{"key":"10.1016\/j.bioorg.2025.109140_bb0115","doi-asserted-by":"crossref","DOI":"10.1002\/chin.201110251","article-title":"Oxadiazole: A biologically important heterocycle","volume":"42","author":"Somani","year":"2011","journal-title":"ChemInform"},{"key":"10.1016\/j.bioorg.2025.109140_bb0120","doi-asserted-by":"crossref","DOI":"10.2174\/0118741045372896250619051210","article-title":"Recent advances in synthetic approaches for 1, 3, 4-Oxadiazole derivatives: a comprehensive review on therapeutic applications","volume":"19","author":"Khamkar","year":"2025","journal-title":"The Open Medicinal Chemistry Journal"},{"key":"10.1016\/j.bioorg.2025.109140_bb0125","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3390\/molecules26041163","article-title":"Green synthetic approach: an efficient eco-friendly tool for synthesis of biologically active oxadiazole derivatives","volume":"26","author":"Banik","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109140_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1096\/fasebj.13.1.9","article-title":"Vascular endothelial growth factor (VEGF) and its receptors","volume":"13","author":"Neufeld","year":"1999","journal-title":"FASEB J."},{"key":"10.1016\/j.bioorg.2025.109140_bb0135","doi-asserted-by":"crossref","first-page":"7311","DOI":"10.1073\/pnas.86.19.7311","article-title":"Isolation and characterization of a vascular endothelial cell mitogen produced by pituitary-derived folliculo stellate cells","volume":"86","author":"Gospodarowicz","year":"1989","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.109140_bb0140","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/0006-291X(89)92678-8","article-title":"Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells","volume":"161","author":"Ferrara","year":"1989","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.bioorg.2025.109140_bb0145","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0150","first-page":"E2900","article-title":"VEGF-B promotes cancer metastasis through a VEGF-A\u2013independent mechanism and serves as a marker of poor prognosis for cancer patients","volume":"112","author":"Yang","year":"2015","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.bioorg.2025.109140_bb0155","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.cell.2013.01.036","article-title":"Targeting placental growth factor\/neuropilin 1 pathway inhibits growth and spread of medulloblastoma","volume":"152","author":"Snuderl","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.bioorg.2025.109140_bb0160","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1080\/14756366.2021.2015342","article-title":"1, 3, 4-Oxadiazole-naphthalene hybrids as potential VEGFR-2 inhibitors: design, synthesis, antiproliferative activity, apoptotic effect, and in silico studies","volume":"37","author":"Hagras","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0165","doi-asserted-by":"crossref","first-page":"27801","DOI":"10.1039\/D3RA05689A","article-title":"Synthesis, biological evaluation and computer-aided discovery of new thiazolidine-2, 4-dione derivatives as potential antitumor VEGFR-2 inhibitors","volume":"13","author":"Elkady","year":"2023","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109140_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2025.102217","article-title":"Rational design, and synthesis of imidazole ring incorporated Pyridine-1, 2, 4-oxadiazole derivatives: in-vitro anticancer evaluation and in-silico molecular docking simulations","volume":"15","author":"Vasamsetti","year":"2025","journal-title":"Results in Chemistry"},{"key":"10.1016\/j.bioorg.2025.109140_bb0175","doi-asserted-by":"crossref","first-page":"6801","DOI":"10.1021\/acsomega.4c08885","article-title":"Novel Benzimidazole\u2013Oxadiazole derivatives as anticancer agents with VEGFR2 inhibitory activity: design, synthesis, in vitro anticancer evaluation, and in silico studies","volume":"10","author":"\u00c7evik","year":"2025","journal-title":"ACS Omega"},{"key":"10.1016\/j.bioorg.2025.109140_bb0180","doi-asserted-by":"crossref","first-page":"36134","DOI":"10.1021\/acsomega.5c03795","article-title":"Targeting Cancer with new Morpholine-Benzimidazole-Oxadiazole derivatives: synthesis, biological evaluation, and computational insights","volume":"10","author":"Halimi Syla","year":"2025","journal-title":"ACS omega"},{"key":"10.1016\/j.bioorg.2025.109140_bb0185","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22186","article-title":"Synthesis, docking study, and antitumor evaluation of benzamides and oxadiazole derivatives of 3-phenoxybenzoic acid as VEGFR-2 inhibitors","volume":"85","author":"Heriz","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0190","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.22218","article-title":"New benzimidazole-oxadiazole derivatives as potent VEGFR-2 inhibitors: synthesis, anticancer evaluation, and docking study","volume":"85","author":"Acar \u00c7evik","year":"2024","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.139012","article-title":"Investigation of anticancer effects of novel piperidine-oxadiazole and piperidine-triazole derivatives as VEGFR inhibitors and evaluation of their molecular docking-dynamic studies","volume":"1316","author":"Osmaniye","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109140_bb0200","doi-asserted-by":"crossref","first-page":"45","DOI":"10.32552\/2024.ActaMedica.950","article-title":"Investigation of the anticancer, antimigration and antiangiogenesis effects of an oxadiazole derivative in two-and three-dimensional cultured Ishikawa and Huvec cells; in vitro and in silico studies","volume":"55","author":"B\u00fclb\u00fcl","year":"2024","journal-title":"Acta Medica Cordoba"},{"key":"10.1016\/j.bioorg.2025.109140_bb0205","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.3390\/catal13101353","article-title":"Electrochemical synthesis of versatile pyrimidine and Oxadiazoles tethered Triazoles as inhibitors of VEGFR-2 in human breast Cancer cells","volume":"13","author":"Ravish","year":"2023","journal-title":"Catalysts"},{"key":"10.1016\/j.bioorg.2025.109140_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdc.2023.101073","article-title":"Design, synthesis and anticancer assessment of 1, 2, 3-triazole incorporated 1, 3, 4-oxadiazole-quinazoline derivatives","volume":"48","author":"Bhogireddy","year":"2023","journal-title":"Chemical Data Collections"},{"key":"10.1016\/j.bioorg.2025.109140_bb0215","doi-asserted-by":"crossref","first-page":"8131","DOI":"10.3390\/molecules27238131","article-title":"Silver (I) complexes based on oxadiazole-functionalized \u03b1-aminophosphonate: synthesis, structural study, and biological activities","volume":"27","author":"Hkiri","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109140_bb0220","doi-asserted-by":"crossref","first-page":"246","DOI":"10.3390\/ph15020246","article-title":"Design, synthesis, and biological evaluation of a novel VEGFR-2 inhibitor based on a 1, 2, 5-oxadiazole-2-oxide scaffold with MAPK signaling pathway inhibition","volume":"15","author":"Mahnashi","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109140_bb0225","doi-asserted-by":"crossref","first-page":"8694","DOI":"10.3390\/molecules27248694","article-title":"2, 5-Bis (2, 2, 2-trifluoroethoxy) phenyl-tethered 1, 3, 4-Oxadiazoles derivatives: synthesis, in silico studies, and biological assessment as potential candidates for anti-cancer and anti-diabetic agent","volume":"27","author":"Shankara","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109140_bb0230","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s13065-021-00757-y","article-title":"Synthesis, biological evaluation and docking studies of 1, 2, 4-oxadiazole linked 5-fluorouracil derivatives as anticancer agents","volume":"15","author":"Bommera","year":"2021","journal-title":"BMC chemistry"},{"key":"10.1016\/j.bioorg.2025.109140_bb0235","doi-asserted-by":"crossref","first-page":"8321400","DOI":"10.1155\/2021\/8321400","article-title":"Inhibition of vascular smooth muscle and cancer cell proliferation by new VEGFR inhibitors and their immunomodulator effect: design, synthesis, and biological evaluation","volume":"2021","author":"Ran","year":"2021","journal-title":"Oxidative Med. Cell. Longev."},{"key":"10.1016\/j.bioorg.2025.109140_bb0240","first-page":"753","article-title":"Synthesis of novel Oxadiazole derivatives, molecular properties prediction and molecular docking studies, journal of the Turkish chemical society section a","volume":"7","author":"Kurt","year":"2020","journal-title":"Chemistry"},{"key":"10.1016\/j.bioorg.2025.109140_bb0245","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1023\/A:1008209720526","article-title":"Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials","volume":"8","author":"Voldborg","year":"1997","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.bioorg.2025.109140_bb0250","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1080\/14756366.2022.2062752","article-title":"Design, synthesis, and anti-cancer evaluation of new pyrido [2, 3-d] pyrimidin-4 (3H)-one derivatives as potential EGFRWT and EGFRT790M inhibitors and apoptosis inducers","volume":"37","author":"Elzahabi","year":"2022","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0255","doi-asserted-by":"crossref","first-page":"65725","DOI":"10.1039\/C6RA08517B","article-title":"Structure guided design and binding analysis of EGFR inhibiting analogues of erlotinib and AEE788 using ensemble docking, molecular dynamics and MM-GBSA","volume":"6","author":"Sharma","year":"2016","journal-title":"RSC Adv."},{"key":"10.1016\/j.bioorg.2025.109140_bb0260","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.3390\/ijms24032651","article-title":"Small molecule EGFR inhibitors as anti-cancer agents: discovery, mechanisms of action, and opportunities","volume":"24","author":"Zubair","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bioorg.2025.109140_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0282586","article-title":"Anticancer derivative of the natural alkaloid, theobromine, inhibiting EGFR protein: computer-aided drug discovery approach","volume":"18","author":"Eissa","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.bioorg.2025.109140_bb0270","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1389450053765879","article-title":"The ErbB receptors and their ligands in cancer: an overview","volume":"6","author":"Normanno","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.bioorg.2025.109140_bb0275","doi-asserted-by":"crossref","first-page":"R42","DOI":"10.1186\/bcr2596","article-title":"Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics","volume":"12","author":"J\u00f6nsson","year":"2010","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0280","first-page":"4892","article-title":"Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2","volume":"61","author":"Cuello","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0285","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/416279b","article-title":"Herceptin acts as an anti-angiogenic cocktail","volume":"416","author":"Izumi","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.bioorg.2025.109140_bb0290","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/cancers9040027","article-title":"EGFR family members\u2019 regulation of autophagy is at a crossroads of cell survival and death in cancer","volume":"9","author":"Henson","year":"2017","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bioorg.2025.109140_bb0295","doi-asserted-by":"crossref","first-page":"11870","DOI":"10.1039\/D5NJ01451D","article-title":"Synthesis and evaluation of edaravone-1, 3, 4-oxadiazole derivatives as potential anti-cancer inhibitors","volume":"49","author":"Reddy","year":"2025","journal-title":"New J. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0300","unstructured":"K. Sambaru, S. Gandamalla, S. Mavurapu, S. Venkatesan, T.R. Allaka, New 1, 3, 4-Oxadiazole and 1, 2, 3-Triazole derivatives as anti-proliferative agents: design, synthesis, biological evaluation, in silico docking and Dft studies, Silico Docking and Dft Studies."},{"key":"10.1016\/j.bioorg.2025.109140_bb0305","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1002\/jccs.70025","article-title":"Substituted 1, 3, 4-oxadiazole coupled 1, 2, 3-triazole derivatives as antiproliferative agents: design, synthesis, biological evaluation and in silico studies","volume":"72","author":"Gandamalla","year":"2025","journal-title":"J. Chin. Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109140_bb0310","article-title":"Design, synthesis, in silico ADME, toxicity prediction, molecular docking studies of 1, 2, 4-oxadiazole incorporated indolizine-thiadiazole derivatives and their biological evaluation as anticancer agents","volume":"134709","author":"Ketha","year":"2025","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2025.109140_bb0315","first-page":"127","article-title":"Exploring 1, 3, 4-oxadiazole derivatives for hepatocellular carcinoma: synthesis, and bioactivity evaluation, journal of applied","volume":"13","author":"Patidar","year":"2025","journal-title":"Pharm. Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0320","first-page":"1","article-title":"Investigating the anticancer activity of novel 1, 2, 4-Oxadiazole-linked 1, 2, 3-Triazole moieties via EGFR\/pI3K\/mTOR Cascade Down-regulation, Polycyc","author":"Ayoup","year":"2025","journal-title":"Aromatic Compounds"},{"key":"10.1016\/j.bioorg.2025.109140_bb0325","article-title":"Synthesis of Quinazoline-1, 3, 4-Oxadiazole linked 1, 2, 3-Triazole hybrids as potent EGFR targeting Antilung Cancer agents","volume":"10","author":"Peddapelli","year":"2025","journal-title":"In Vitro, In Silico, and DFT Studies, ChemistrySelect"},{"key":"10.1016\/j.bioorg.2025.109140_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/ddr.70061","article-title":"Design, synthesis and molecular docking of new Thieno [2, 3-d] Pyrimidin-4-one derivatives as dual EGFR and FGFR inhibitors","volume":"86","author":"Sultan","year":"2025","journal-title":"Drug Dev. Res."},{"key":"10.1016\/j.bioorg.2025.109140_bb0335","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107935","article-title":"Synthesis of S-alkylated oxadiazole bearing imidazo [2, 1-b] thiazole derivatives targeting breast cancer: in vitro cytotoxic evaluation and in vivo radioactive tracing studies","volume":"153","author":"Mohammed","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.cdc.2024.101167","article-title":"Design, synthesis, characterization, invitro anticancer evaluation, computational studies, and in silico ADME assessment of new N-(5-o-tolyl-1, 3, 4-oxadiazol-2-yl) alkanamides","volume":"54","author":"Md","year":"2024","journal-title":"Chemical Data Collections"},{"key":"10.1016\/j.bioorg.2025.109140_bb0345","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1039\/D4MD00055B","article-title":"Computational design, synthesis, and assessment of 3-(4-(4-(1, 3, 4-oxadiazol-2-yl)-1 H-imidazol-2-yl) phenyl)-1, 2, 4-oxadiazole derivatives as effective epidermal growth factor receptor inhibitors: a prospective strategy for anticancer therapy","volume":"15","author":"Khedkar","year":"2024","journal-title":"RSC Medicinal Chemistry"},{"key":"10.1016\/j.bioorg.2025.109140_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138209","article-title":"Design and synthesis of some new imidazole-morpholine-1, 2, 4-oxadiazole hybrids as EGFR targeting in vitro anti-breast cancer agents","volume":"1310","author":"Kannekanti","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109140_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2024.138741","article-title":"Pyridine-based glycosides bearing 1, 2, 4-triazole and their 1, 3, 4-oxadiazole analogues as potential EGFR and CDK-2 inhibitors: design, synthesis, antiproliferative activity and in silico studies","volume":"1313","author":"Kassem","year":"2024","journal-title":"J. Mol. Struct."},{"key":"10.1016\/j.bioorg.2025.109140_bb0360","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1080\/10406638.2023.2257849","article-title":"Anti-proliferative, anti-EGFR and in silico studies of a series of new imidazole tethered 1, 2, 4-Oxadiazoles","volume":"44","author":"Lavunuri","year":"2024","journal-title":"Polycyc. Aromatic Compounds"},{"key":"10.1016\/j.bioorg.2025.109140_bb0365","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13065-023-01003-3","article-title":"Chalcone\/1, 3, 4-Oxadiazole\/Benzimidazole hybrids as novel anti-proliferative agents inducing apoptosis and inhibiting EGFR & BRAFV600E","volume":"17","author":"Hagar","year":"2023","journal-title":"BMC chemistry"},{"key":"10.1016\/j.bioorg.2025.109140_bb0370","first-page":"97","article-title":"New Oxadiazole\/Benzimidazole Hybrids: Design","volume":"6","author":"Hagar","year":"2023","journal-title":"Synthesis, and Molecular Docking Studies, Journal of Advanced Biomedical and Pharmaceutical Sciences"},{"key":"10.1016\/j.bioorg.2025.109140_bb0375","doi-asserted-by":"crossref","first-page":"2200009","DOI":"10.1002\/ardp.202200009","article-title":"New 1, 3, 4-oxadiazoles linked with the 1, 2, 3-triazole moiety as antiproliferative agents targeting the EGFR tyrosine kinase","volume":"355","author":"Mahmoud","year":"2022","journal-title":"Arch. Pharm."},{"key":"10.1016\/j.bioorg.2025.109140_bb0380","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.2174\/1570180820666230410083544","article-title":"Molecular modeling of some 1, 3, 4-Oxadiazole derivatives as EGFR inhibitors for the treatment of Cancer","volume":"21","author":"Patil","year":"2024","journal-title":"Lett. Drug Des. Discovery"},{"key":"10.1016\/j.bioorg.2025.109140_bb0385","first-page":"228","article-title":"Synthesis, cytotoxic effect assessment and molecular docking studies of disubstituted thiadiazole including oxadiazole as hybrid component","volume":"42","author":"Hassanzadeh","year":"2022","journal-title":"Hacettepe University Journal of the Faculty of Pharmacy"},{"key":"10.1016\/j.bioorg.2025.109140_bb0390","article-title":"New molecular hybrids containing benzimidazole, thiazolidine-2, 4-dione and 1, 2, 4-oxadiazole as EGFR directing cytotoxic agents","volume":"124","author":"Saritha","year":"2022","journal-title":"Tetrahedron"},{"key":"10.1016\/j.bioorg.2025.109140_bb0395","doi-asserted-by":"crossref","first-page":"6899","DOI":"10.3390\/molecules27206899","article-title":"Cell cycle arrest and apoptosis-inducing ability of benzimidazole derivatives: design, synthesis, docking, and biological evaluation","volume":"27","author":"Nazreen","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109140_bb0400","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.105124","article-title":"Rational design-aided discovery of novel 1, 2, 4-oxadiazole derivatives as potential EGFR inhibitors","volume":"114","author":"Unadkat","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0405","doi-asserted-by":"crossref","first-page":"870","DOI":"10.3390\/ph14090870","article-title":"Naproxen based 1, 3, 4-oxadiazole derivatives as EGFR inhibitors: design, synthesis, anticancer, and computational studies","volume":"14","author":"Alam","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.bioorg.2025.109140_bb0410","doi-asserted-by":"crossref","first-page":"454","DOI":"10.4103\/1735-5362.297848","article-title":"Synthesis, cytotoxic evaluation, and molecular docking studies of some new 1, 3, 4-oxadiazole-based compounds","volume":"15","author":"Hassanzadeh","year":"2020","journal-title":"Res. Pharm. Sci."},{"key":"10.1016\/j.bioorg.2025.109140_bb0415","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.3390\/molecules25215190","article-title":"In vitro and in silico evaluation of anticancer activity of new indole-based 1, 3, 4-oxadiazoles as EGFR and COX-2 inhibitors","volume":"25","author":"Sever","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.bioorg.2025.109140_bb0420","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.bioorg.2018.11.032","article-title":"1, 3, 4-oxadiazole\/chalcone hybrids: design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities","volume":"84","author":"Fathi","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0425","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111607","article-title":"1, 2, 4-Oxadiazole derivatives targeting EGFR and c-met degradation in TKI resistant NSCLC","volume":"182","author":"Dokla","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0430","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.bioorg.2018.12.039","article-title":"Design and synthesis of new phthalazine-based derivatives as potential EGFR inhibitors for the treatment of hepatocellular carcinoma","volume":"85","author":"Boraei","year":"2019","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111693","article-title":"New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: design, synthesis, cytotoxicity evaluation and in silico studies","volume":"183","author":"El-Sayed","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0440","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s44442-025-00004-2","article-title":"EGFR tyrosine kinase inhibitor: design, synthesis, characterization, biological evaluation, and molecular docking of novel 1, 3, 4-oxadiazole, thio-methyl, and 1, 2, 3-triazole hybrids","volume":"29","author":"Alshamari","year":"2025","journal-title":"J. Saudi Chem. Soc."},{"key":"10.1016\/j.bioorg.2025.109140_bb0445","doi-asserted-by":"crossref","first-page":"2305856","DOI":"10.1080\/14756366.2024.2305856","article-title":"Design, synthesis, and apoptotic antiproliferative action of new 1, 2, 3-triazole\/1, 2, 4-oxadiazole hybrids as dual EGFR\/VEGFR-2 inhibitors","volume":"39","author":"Mahmoud","year":"2024","journal-title":"J. Enzyme Inhib. Med. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0450","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.3390\/biom12111612","article-title":"Computational investigation of 1, 3, 4 oxadiazole derivatives as lead inhibitors of VEGFR 2 in comparison with EGFR: density functional theory, molecular docking and molecular dynamics simulation studies","volume":"12","author":"Bilal","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.bioorg.2025.109140_bb0455","doi-asserted-by":"crossref","first-page":"1447618","DOI":"10.3389\/fchem.2024.1447618","article-title":"Design and synthesis of new 1, 2, 4-oxadiazole\/quinazoline-4-one hybrids with antiproliferative activity as multitargeted inhibitors","volume":"12","author":"Mohamed","year":"2024","journal-title":"Front. Chem."},{"key":"10.1016\/j.bioorg.2025.109140_bb0460","doi-asserted-by":"crossref","first-page":"4297","DOI":"10.1039\/D5MD00454C","article-title":"Design, Synthesis, and Apoptotic Antiproliferative Efficacy of New Quinazoline\/1, 3, 4-Oxadiazole-2-thione Derived EGFR\/HER-2 Dual Inhibitors with Anti-Breast cancer Activity","volume":"16","author":"Gomaa","year":"2025","journal-title":"RSC Medicinal Chemistry"}],"container-title":["Bioorganic Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S004520682501020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T19:14:28Z","timestamp":1763666068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S004520682501020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":92,"alternative-id":["S004520682501020X"],"URL":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109140","relation":{},"ISSN":["0045-2068"],"issn-type":[{"value":"0045-2068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The emerging role of Oxadiazole derivatives as VEGFR and EGFR inhibitors in Cancer therapy","name":"articletitle","label":"Article Title"},{"value":"Bioorganic Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bioorg.2025.109140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109140"}}